Monitoring quinolone resistance due to *Haemophilus influenzae* mutations (2012–17)

Yasuhiro Nagatomo^{a#}, Tetsuro Shirakura^b, Kunihiro Fukuchi^c, Takahiro
Takuma^a, Issei Tokimatsu^a, Yoshihito Niki^a

^aDepartment of Infectious Diseases, Showa University, Showa University, School of
Medicine, Department of Medicine, Tokyo, Japan

^bDepartment of Microbiology, Showa University, Showa University, School of
Medicine, Department of Medicine

^cDepartment of Microbiology, Showa University, Showa University, School of Medicine,
Department of Medicine

Running Head: Quinolone resistance and *H. influenzae* mutations

#Address correspondence to Yasuhiro Nagatomo. nagayasu@med.showa-u.ac.jp

Abstract

Among drug-resistant bacteria of recent concern, we determined minimum inhibitory concentrations (MICs) of six different quinolone antibacterial agents in *Haemophilus influenzae* and performed molecular genetic analysis in addition to the exploration for β -lactamase-producing and β -lactamase negative ampicillin-resistant *H. influenzae* (BLNAR). A total of 144 clinical *H. influenzae* strains isolated at the Showa University Hospital between 2012 and 2017 were subjected to MIC determination for penicillin/quinolone antibacterial agents using the nitrocefin method and the Clinical and Laboratory Standards Institute broth microdilution method. Moreover, amino acid mutations in the quinolone resistance-determining regions (QRDRs) were analyzed in the isolates showing MIC value of ≥ 0.25 $\mu\text{g/ml}$ of quinolone antibacterial agents. Increasing proportions of BLNAR were noted, with 15% in 2015 to 43.5% in 2016 and 63.6% in 2017. Among quinolone antibacterial agents, all isolates remained susceptible to sitafloxacin (STFX), and STFX showed strong inhibitory potencies against both DNA gyrase and topoisomerase IV. For moxifloxacin (MXF), however, strains with MIC value of 0.5 $\mu\text{g/ml}$ were detected every year since 2013 except 2015. Amino acid mutations were investigated in 17 isolates (11.8%) with MXF MIC value of ≥ 0.25 $\mu\text{g/ml}$, and confirmed in 11 isolates (7.6%), of which mutations of GyrA were found in

35 9 isolates. Future antibacterial drug regimens may need to address the emergence of

36 quinolone-resistant *H. influenzae*.

37

38

39 Introduction

40 *Haemophilus influenzae* is the second most common causative bacterium of
 41 community-acquired pneumonia, following *Streptococcus pneumoniae*, and has taken
 42 the leading position after pneumococcal vaccines became popular (1). β -Lactam
 43 antibiotics have previously been used for the treatment of community-acquired
 44 pneumonia. In the 2000s, however, β -lactamase producing ampicillin-resistant (BLPAR)
 45 bacteria have been increasingly detected in Canada (2), Japan, and some other countries.
 46 In addition, β -lactamase negative ampicillin-resistant (BLNAR) bacteria have been
 47 increasingly detected in Japan in the recent years (3). Moreover, BLNAR bacteria
 48 exhibit reduced susceptibility to cepheems, which have high affinity to penicillin binding
 49 protein (PBP) 3, thereby raising a concern regarding the possible acquisition of drug
 50 resistance.

51 Meanwhile, fluoroquinolones are clinically effective against these bacteria (4), and in
 52 particular, have been frequently prescribed to outpatients with respiratory and
 53 otolaryngologic infections. Accordingly, reports on *H. influenzae* resistant to quinolone
 54 antibacterial agents have started emerging in the beginning of 2000. In Spain, a report
 55 has documented that ciprofloxacin (CIP) -insensitive strains accounted for 0.26% and
 56 0.36% in 2005–2009 and 2010–2013, respectively (5), whereas another report has stated

that low-sensitive strains to CIP accounted for 43% in 2007 (6). In Taiwan, the levofloxacin (LVX) resistance rate has been reported to have increased from 2.0% in 2004 to 24.3% in 2010 (7). These data illustrate that the prevalence of quinolone resistance among *H. influenzae* isolates is highly variable depending on when the test is conducted even within the same country or within the same institution. Furthermore, high-level BLNAR strains have been reported to exhibit reduced sensitivity toward fluoroquinolones (8). Thus, it is essential to take into consideration the increasing number of BLNAR isolates and determine the trend of quinolone sensitivity.

Fluoroquinolone resistance is primarily induced through mutations in QRDRs of GyrA gene encoding DNA gyrase or ParC gene encoding topoisomerase IV, which cause three-dimensional structural alterations in the respective enzymes and decrease the affinity between fluoroquinolones and these replication enzymes (9). In the case of *H. influenzae*, drug resistance has been shown to be strongly related to mutations of serine and aspartic acid at positions 84 and 88 of GyrA and of serine at position 84 of ParC (10). However, only a limited number of previous studies have investigated mutations in QRDRs in the same institution over time or have compared MICs among different quinolones. In this study, we tested sensitivity levels to quinolone and penicillin antibacterial agents over 6 years in *H. influenzae* strains that were isolated at

the same institution without effects from clinical departments, diseases, or specimens, and analyzed genetic mutations in QRDRs in strains with MIC value of ≥ 0.25 $\mu\text{g/ml}$ of quinolones. Next, we assessed whether antibacterial efficacies varied among quinolone antibacterial agents or whether the bacteria tended to be resistant.

Results

BLNAR and β -lactamase-producing bacteria. We tested the drug susceptibility using 144 *H. influenzae* strains stored in our laboratory. *H. influenzae* strains had been isolated from respiratory (n = 130), otolaryngologic (n = 6), blood (n = 3), pus (n = 3), and other (n = 2) samples. As per the Clinical and Laboratory Standards Institute guidelines, the tests were performed by the broth microdilution method using plates (11). The test bacterial strain was cultured on chocolate agar medium at 35°C in 5% CO₂ for 22 hours (8). The bacterial strains were seeded in each well at a final inoculum of 5×10^5 CFU/ml. The plates were incubated at 35°C in 5% CO₂ for 22 hours, and MIC values of the test drugs against clinical *H. influenzae* isolates were measured. Furthermore, the β -lactamase producing ability was determined by the nitrocefin method (12). Based on these results, percentages of BLNAR and β -lactamase-producing bacteria over time are shown in Figure 1. Among all tested strains, BLNAR strains accounted for 38.9% in

2012, 22.2% in 2013, 37.0% in 2014, 15.0% in 2015, 43.5% in 2016, and 63.6% in 2017, and the percentage of BLNAR strains was found to have consecutively increased in 2016 and 2017. In 2017, aminobenzylpenicillin (ABPC)-resistant strains, including β -lactamase-producing ones, accounted for 78.8% of all isolates. β -Lactamase producing amoxicillin/clavulanic acid resistant *H. influenzae* (BLPACR) was not detected.

Susceptibility to quinolones. MIC values of various quinolone antibacterial agents measured with 144 *H. influenzae* isolates are shown for each year (Figure 2a–f). For all quinolones, not resistant strains as defined with MIC value of ≥ 2 $\mu\text{g/ml}$ were found. Five quinolone antibacterial agents, except MXF, remained effective with MIC values of ≤ 0.03 $\mu\text{g/ml}$ against approximately 90% of isolates each year (Figure 2b–f). For STFX in particular, no strains showing MIC values of ≥ 0.12 $\mu\text{g/ml}$ were detected during the study period (Figure 2f).

Comparison of susceptibility to MXF and other quinolones. Meanwhile, for MXF, a certain number of isolates with MIC values of ≥ 0.5 $\mu\text{g/ml}$ were detected every year since 2013 except 2015, and isolates with MIC value of ≤ 0.03 $\mu\text{g/ml}$ accounted for less than 80% of isolates every year (Figure 2a). The MXF MIC value and relative MIC values of other quinolones against the same strain were compared. In an MIC range of 0.25–1.0

µg/ml, 64.7%, 70.6%, 76.5%, 88.2%, and 100% of the 144 strains tested showed MIC values of CIP (Figure 3a), LVX (Figure 3b), garenoxacin (GRNX), tosufloxacin (TFLX), and STFX (not shown in Figure) which were lower than that of MXF. This series of results demonstrated that the antibacterial potency of MFLX was clearly lower than that of any other antibacterial agent tested.

Amino acid mutations in QRDRs of GyrA and ParC. We investigated amino acid mutations in QRDRs of GyrA and ParC in 17 strains with low susceptibility to MXF (MIC ≥ 0.25 µg/ml) like a report described by Shoji et al (13). Genomic DNA of *H. influenzae* was purified, and any gene encoding QRDRs was PCR-amplified. Based on the nucleotide sequences thus obtained, amino acid sequences were analyzed, and amino acid mutations in QRDRs were identified. Mutations were found in 11 strains, and detected every year except 2015 (Table 1). Detection rates were 11.1% in 2012, 5.6% in 2013, 14.8% in 2014, 8.3% in 2016, and 5.3% in 2017 (total 7.6%). Only one mutation was found in GyrA (Ser84Leu) in 8 strains or in ParC (Ser84Ile or Gly82Arg) in 2 strains, and one mutation each in GyrA (Ser84Leu) and ParC (Ser84Ile). Both strains with the Ser84Ile mutation had MXF MIC ≥ 0.5 µg/ml, CIP MIC = 1 µg/ml, GRNX MIC ≥ 0.25 µg/ml, LVX MIC = 0.5 µg/ml, and TFLX MIC = 1 µg/ml, which indicated reduced susceptibility.

BLNAR and amino acid mutations in QRDRs. Of the 11 isolates with any amino acid mutation, 5 (2012-2, 2014-1, 2014-3, 2017-1, and 2017-2) were BLNAR, and all but 2012-2 exhibited reduced susceptibility to fluoroquinolones except for STFX (Table 1).

Discussion

In Japan, no Hib strains have been detected in children with invasive infections after Hib vaccines were introduced in 2008 (14). However, the frequency of isolation of BLNAR strains has not decreased; It is rather high in some areas, with 33.5% reported in the respiratory area in 2010 (15), 35.8% in the otorhinolaryngology area in 2012 (3), and 46.7% in the pediatric respiratory area in 2012 (16). Additionally, the present study showed that the frequency of isolation of BLNAR strains increased to 63.6% in 2017 (Figure 1).

Fluoroquinolone resistance rates of *H. influenzae* previously studied in Japan were extremely low, and the 2010 respiratory specimen surveillance report also stated that the resistance to CIP and LVX was found in 0.5% and STFX resistance was found in 0% of isolates (15). STFX is characterized by the strong inhibitory potencies against both DNA gyrase and topoisomerase IV (17). The well-preserved STFX sensitivity owing to

this characteristic was consistent with that reported in other reports (8,13) and the present findings.

Meanwhile, the MXF resistance rate in *H. influenzae* isolates has been reported to be 1.1% in 2010 (15); however, it is noteworthy that low susceptibility to MXF was observed for 11.8% (17 of 144) of isolates collected from 2012 to 2017 in the present study. This is likely to be attributable to the fact that MXF can be orally administered in Japan, whereas injectable formulations are available in Europe and the United States. The mutant prevention concentration of MXF for *H. influenzae* has been reported to be 0.125–0.25 µg/ml (18). However, the resistance may be acquired if the MXF level in blood does not sufficiently increase because an antacid or laxative, for example, is concomitantly used with oral MXF. Furthermore, the drug resistance epidemic status in the area should be understood.

Additionally, MIC values of LVX and GRNX, which are frequently used in Japan, and MIC value of CIP, which is often used against *Pseudomonas aeruginosa*, also tended to be elevated. In 2017, two isolates with TFLX MIC = 1 µg/ml (one from a child) were identified (Figure 2e). After the recent approval for treatment of respiratory infections in children as an additional indication in Japan, opportunities of prescribing

TFLX are increasing, and there is a concern that this might lead to an increase in the prevalence of TFLX resistance.

Considering that MIC value of MXF is relatively higher than the MIC values of other quinolones (Figure 3a,b) and two of six isolates with MXF MIC value of 0.25 µg/ml had amino acid mutations in QRDRs (Table 1), MIC values of MXF appear to be more useful than those of other quinolones as a reference to find bacterial isolates with reduced susceptibility to quinolone antibacterial agents. Therefore, we believe that MXF is suited for MIC assays to screen bacterial isolates with reduced susceptibility to fluoroquinolones, particularly in Japan. Furthermore, considering the reports by Shoji (13) and Perez (6), we propose that an MXF MIC value of 0.25 µg/ml is an appropriate threshold to screen bacterial isolates for amino acid mutations in QRDRs. QRDR mutations are found more frequently at Ser84 and Asp88 of GyrA gene and at Ser84, Glu88, and Gly82 of ParC gene than at other positions (5,8,13). In the case of *H. influenzae*, previous studies have demonstrated that MICs increase when strains have mutations at Ser84 in GyrA QRDRs or at Gly82 or Ser84 in ParC QRDRs (5,7,13). In this study, we analyzed 17 isolates showing MXF MIC value of ≥ 0.25 µg/ml and found that 9 isolates had a leucine mutation at Ser84 of GyrA gene (Table 1), a finding that is consistent with previous reports. Considering the reports on *Escherichia coli*, *Klebsiella*

pneumoniae (19), *Enterococcus faecalis* (20), and other bacteria, this finding suggests that GyrA is a likely primary target of quinolones for their antimicrobial activity similarly, against *H. influenzae*.

In this study, 2012-2 and 2017-1 isolates were found to have mutations only in ParC (Table 1). Related to this result, Shoji et al obtained a mutant with the mutation only at Ser84 of ParC gene among hot spots in a resistance induction experiment (13). The MXF MIC for this mutant was 0.5 µg/ml, indicating low susceptibility. This induction experiment showed that Ser84 is an important mutation site for *H. influenzae* to acquire quinolone resistance, supporting the finding in the clinical isolates in the present study.

While MIC values have been reported to increase as the number of QRDR mutations increases (13,21), only one isolate was found to have two mutations in the present study. The isolate 2017-2 showed reduced susceptibility to all fluoroquinolones except for STFX, a finding supporting the above notion (Table 1).

Isolate 2014-5 showed a high MIC value (0.5 µg/ml) for not only MXF but also CIP and LVX, although this isolate had no mutations in QRDRs of both GyrA and ParC enzymes (Table 1). A factor presumably involved in this is a drug efflux pump (*acrAB*) (21,22) or *H. influenzae*-specific porin (23,24), the protein structure of which is similar

to that of porin (OmpF); however, solid evidence was not obtained from the present study, and this point remains to be addressed in future studies.

It is difficult to predict whether the frequency of quinolone-resistant *H. influenzae* isolates will increase in the future. Nevertheless, we consider that an outbreak of quinolone-resistant *H. influenzae* is likely to occur because the population aged >65 years is a risk factor for this resistance (7), quinolone-resistant *E. coli* is increasing rapidly over recent years, and quinolone-resistant *E. coli* isolates also have mutations in DNA gyrase and topoisomerase IV (19). In 2015, a global action plan on antimicrobial resistance (AMR) was adopted by the World Health Assembly, and member countries developed national action plans. In Japan, a milestone is to halve the amount of use of broad-spectrum oral antibacterial agents, including oral fluoroquinolones by 2020. Therefore, monitoring the trend of occurrence of fluoroquinolone resistant *H. influenzae* isolates is likely to have a substantial meaning to AMR countermeasures.

In clinical practice, the presence of a drug resistance gene does not necessarily indicate that the isolate has a reduced susceptibility to that antibacterial agent (i.e., silence mutations) (25). However, acquisition of quinolone resistance is facilitated by the use of quinolones. Therefore, the emergence of quinolone-resistant bacteria can be prevented and future medical care against infectious diseases would benefit if we can

eliminate the unnecessary use of antibacterial drugs by promoting proper use of antibacterial drugs. Limitations of this study include that we could not follow clinical courses of cases in which isolates with low quinolone susceptibility were found and that we could not determine the resistance status in other institutions. Close monitoring of changes in drug resistance and clinical characteristics should be jointly performed at multiple sites.

Materials and Methods

Bacterial strains. A total of 144 *H. influenzae* strains that had been clinically isolated at the Showa University Hospital between 2012 and 2017 and stored in our laboratory were used in this study.

β -Lactamase-producing ability test. Each bacterial strain was cultured on chocolate agar medium (Nippon Beckton-Dickinson, Tokyo, Japan) at 35°C in 5% CO₂ for 22 hours (8), and then nitrocefin (Kantokagaku, Tokyo, Japan) was added in drops to *H. influenzae*; the strain was considered to be capable of producing β -lactamase when the red color developed (12).

Drug susceptibility assay. Susceptibility to antibacterial agents was measured by the Clinical and Laboratory Standards Institute broth microdilution method using 96-well

234 plates (11). As a basal medium, the liquid medium added to each well was HTM
235 medium (Eiken, Tokyo, Japan) and was supplemented with Hematin (15 µg/ml) and
236 NAD (15 µg/ml) (Eiken Chemical, Class I bacteria test series, frozen plates). Each
237 strain was cultured on a chocolate agar medium at 35°C in 5% CO₂ for 22 hours, and
238 then a bacterial suspension was prepared at a concentration adjusted to be similar to that
239 of McFarland standard (bioMérieux) 0.5 using physiological saline. Finally, each well
240 was inoculated with a bacterial suspension (5×10^5 CFU/ml). The plate was cultured at
241 35°C in 5% CO₂ for 22 hours, and MIC values of test drugs for these bacteria were
242 measured. The following test drugs were used:

243 aminobenzylpenicillin (ABPC), sulbactam/ampicillin (SAM), clavulanic
244 acid/amoxicillin (AMC), levofloxacin (LVX), ciprofloxacin (CIP), garenoxacin
245 (GRNX), moxifloxacin (MXF), tosufloxacin (TFLX), and sitafloxacin (STFX).

246 **Analysis of QRDR amino acid sequences.** *H. influenzae* strains showing MXF MIC
247 value of ≥ 0.25 µg/ml in the drug susceptibility assay were selected as test strains and
248 allowed to grow. From bacterial cells of the test strains, genomic DNA was extracted
249 using Sepa-Gene (EIDIA Co., Ltd., Tokyo, Japan), allowed to aggregate by adding
250 99.5% alcohol, centrifuged at 8000 ×g to precipitate, and then washed with 70% alcohol.
251 Using the resulting DNA sample as a template, genes encoding QRDRs were amplified

by PCR. For amplification, a mixture solution of *Taq* polymerase (Roche, Mannheim, Germany) and primer (26) was used in a T100 thermocycler (BIORAD, CA, USA) under PCR conditions similar to those described by Shoji et al (13).

Next, the PCR product was subjected to purification/separation and extraction as follows. The entire PCR product was subjected to electrophoresis in 2% agarose gel (TAKARA, Shiga, Japan) under 120 V/h for 1 hour in Tris-borate-EDTA (NIPPON GENE, Tokyo, Japan) buffer. Then, the gel was stained with ethidium bromide to detect the target PCR product bands (GyrA: 375 bp, ParC: 370 bp), and the detected bands were excised. Thereafter, from the excised gel segments, DNA was extracted and purified using a GenElute Minus EtBr Spin Column (SIGMA-ALDRICH, St. Louis, USA) and concentrated with ethanol. For direct sequencing using the resulting DNA samples as templates, PCR amplification was performed using Big Dye Terminator v1.1 cycle sequencing kit (Applied Biosystems Japan, Tokyo, Japan). The PCR primers described above were used here as sequence primers.

The resulting sequencing solutions were analyzed using an ABI PRISM 310 genetic analyzer (Applied Biosystems, Foster City, CA), and nucleotide sequences of the target gene regions were determined. Based on the nucleotide sequence data

269 obtained, amino acid sequences were analyzed using GENETYX Ver. 8 (GENETYX,
270 Tokyo, Japan) to find amino acid mutations in QRDRs.

271

272 Acknowledgments: This work was supported by Kazuhisa Ugajin. We thank Zhao WH
273 for providing the nitrocefin reagent.

274 Transparency declarations: We have no Conflict of Interest to declare. This research
275 received no specific grant from any funding agency in the public, commercial, or
276 not-for-profit sectors.

277

References

1. Domenech M, Garcia E. 2017. *N* -acetyl-L-cysteine and cysteamine as new strategies against mixed biofilms of nonencapsulated *Streptococcus pneumoniae* and Nontypeable *Haemophilus influenzae*. Antimicrob Agents Chemother 61:e01992–16.
2. Tsang RSW, Shuel M, Whyte K, Hoang L, Tyrrell G, Horsman G, Wylie J, Jamieson F, Lefebvre B, Haldane D, Gad RR, German GJ, Needle R. 2017. Antibiotic susceptibility and molecular analysis of invasive *Haemophilus influenzae* in Canada, 2007 to 2014. J Antimicrob Chemother 72:1314–1349. <https://doi.org/10.1093/jac/dkw565>.
3. Suzuki K, Kurono Y, Ikeda K, Watanabe A, Iwamoto A, Totsuka K, Kaku M, Iwata S, Kadota J, Hanaki H. 2015. Nationwide surveillance of 6 otorhinolaryngological infectious diseases and antimicrobial susceptibility pattern in the isolated pathogens in Japan. J Infect Chemother 21:483–491. <https://dx.doi.org/10.1016/j.jiac.2015.03.005>.
4. Nakai H, Sato T, Uno T, Furukawa E, Kawamura M, Takahashi H, Watanabe A, Fujimura S. 2018. Mutant selection window of four quinolone antibiotics against clinical isolates of *Streptococcus pneumoniae*, *Haemophilus influenzae* and

- 296 *Moraxella catarrhalis*. J Infect Chemother 24:83–87.
- 297 <https://doi.org/10.1016/j.jiac.2017.08.009>.
- 298 5. Puig C, Tirado-Velez JM, Calatayud L, Tubau F, Garmendia J, Ardanuy C, Marti
299 S, de la Campa AG, Linares J. 2015. Molecular characterization of
300 fluoroquinolone resistance in nontypeable *Haemophilus influenzae* clinical
301 isolates. Antimicrob Agents Chemother 59:461–466.
302 <https://doi.org/10.1128/AAC.04005-14>.
- 303 6. Perez-Vazquez M, Roman F, Garcia-Cobos S, Campos J. 2007. Fluoroquinolone
304 resistance in *Haemophilus influenzae* is associated with hypermutability.
305 Antimicrob Agents Chemother 51:1566–1569.
306 <https://doi.org/10.1128/AAC.01437-06>.
- 307 7. Kuo SC, Chen PC, Shiau YR, Wang HY, Lai JF, Huang W, Lauderdale TL. 2014.
308 Levofloxacin-resistant *Haemophilus influenzae*, Taiwan, 2004-2010. Emerg
309 Infect Dis 20:1386–1390. <https://doi.org/10.3201/eid2008.140341>.
- 310 8. Honda H, Sato T, Shinagawa M, Fukushima Y, Nakajima C, Suzuki Y, Shiraishi
311 T, Kuronuma K, Takahashi S, Takahashi H, Yokota SI. 2018. Multiclonal
312 expansion and high prevalence of β -lactamase-negative high-level
313 ampicillin-resistant *Haemophilus influenzae* in Japan, and susceptibility to

- 314 quinolones. Antimicrob Agents Chemother 62.pii:e00851-18.
- 315 <https://doi.org/10.1128/AAC.00851-18>.
- 316 9. Correia S, Poeta P, Hebraud M, Capelo JL, Igrejas G. 2017. Mechanisms of
- 317 quinolone action and resistance: Where do we stand?. J Med Microbiol 66:551–
- 318 559. <https://doi.org/10.1099/jmm.0.000475>.
- 319 10. Kondo H, Ito S, Hatazaki K, Horie K, Nakane K, Mizutani K, Tsuchiya T,
- 320 Yasuda M, Yokoi S, Nakano M, Deguchi T. 2018. GyrA and/or ParC alterations
- 321 of *Haemophilus influenzae* strains isolated from the urethra of men with acute
- 322 urethritis. J Infect Chemother 24:232–235.
- 323 <https://doi.org/10.1016/j.jiac.2017.10.013>.
- 324 11. Clinical and Laboratory Standards Institute. 2017. Performance standards for
- 325 antimicrobial susceptibility testing. CLSI M100-S27.CLSI, Wayne, PA, USA.
- 326 12. Bidya S, Suman RS. 2014. Comparative study of three β lactamase test methods
- 327 in *Staphylococcus aureus* isolated from two Nepalese hospitals. Open Journal of
- 328 Clinical Diagnosis 4:47–52. <https://dx.doi.org/10.4236/oicd.2014.41009>.
- 329 13. Shoji H, Shirakura T, Fukuchi K, Takuma T, Hanaki H, Tanaka K, Niki Y. 2014.
- 330 A molecular analysis of quinolone-resistant *Haemophilus influenzae*: Validation

- 331 of the mutations in Quinolone Resistance-Determining Regions. J Infect
332 Chemother 20:250–255. <https://dx.doi.org/10.1016/j.jiac.2013.12.007>.
- 333 14. Suga S, Ishiwada N, Sasaki Y, Akeda H, Nishi J, Okada K, Fujieda M, Oda M,
334 Asada K, Nakano T, Saitoh A, Hosoya M, Togashi T, Matsuoka M, Kimura K,
335 Shibayama K. 2018. A nationwide population-based surveillance of invasive
336 *Haemophilus influenzae* diseases in children after the introduction of the
337 *Haemophilus influenzae* type b vaccine in Japan. Vaccine 36:5678–5684.
338 <https://doi.org/10.1016/j.vaccine.2018.08.029>
- 339 15. Yanagihara K, Kadota J, Aoki N, Matsumoto T, Yoshida M, Yagisawa M, Oguri
340 T, Sato J, Ogasawara K, Wakamura T, Sunakawa K, Watanabe A, Iwata S, Kaku
341 M, Hanaki H, Ohsaki Y, Watari A, Toyoshima E, Takeuchi K, Shiokoshi M,
342 Takeda H, Miki M, Kumagai T, Nakanowatari S, Takahashi H, Utagawa M,
343 Nishiya H, Kawakami S, Kobayashi N, Takasaki J, Mezaki K, Konosaki H, Aoki
344 Y, Yamamoto Y, Shoji M, Goto H, Saraya T, Kurai D, Okazaki M, Niki Y,
345 Yoshida K, Kawana A, Saionji K, Fujikura Y, Miyazawa N, Kudo M, Sato Y,
346 Yamamoto M, Yoshida T, Nakamura M, Tsukada H, Imai Y, Tsukada A,
347 Kawasaki S, Honma Y, Yamamoto T, Ban N, Mikamo H, Sawamura H, Miyara T,
348 Toda H, Sato K, Nakamura T, Fujikawa Y, Mitsuno N, Mikasa K, Kasahara K,

- 349 Sano R, Sugimoto K, Asari S, Nishi I, Toyokawa M, Miyashita N, Koguchi Y,
350 Kusano N, Mihara E, Kuwabara M, Watanabe Y, Kawasaki Y, Takeda K,
351 Tokuyasu H, Masui K, Negayama K, Hiramatsu K, Aoki Y, Fukuoka M,
352 Magarifuchi H, Nagasawa Z, Suga M, Muranaka H, Morinaga Y, Honda J, Fujita
353 M. 2015. Nationwide surveillance of bacterial respiratory pathogens conducted
354 by the surveillance committee of Japanese Society of Chemotherapy, the
355 Japanese Association for Infectious Diseases, and the Japanese Society for
356 Clinical Microbiology in 2010: General view of the pathogens' antibacterial
357 susceptibility. J Infect Chemother 21:410–420.
358 <https://dx.doi.org/10.1016/j.jiac.2015.02.008>.
- 359 16. Shiro H, Sato Y, Toyonaga Y, Hanaki H, Sunakawa K. 2015. Nationwide survey
360 of the development of drug resistance in the pediatric field in
361 2000–2001, 2004, 2007, 2010 and 2012: Evaluation of the changes in drug
362 sensitivity of *Haemophilus influenzae* and patients' background factors. J Infect
363 Chemother 21:247–256. <https://dx.doi.org/10.1016/j.jiac.2014.11.012>.
- 364 17. Hamasuna R, Ohnishi M, Matsumoto M, Okumura R, Ueno M, Matsumoto T.
365 2018. In vitro activity of sitafloxacin and additional newer generation

- 366 fluoroquinolones against ciprofloxacin-resistant *Neisseria gonorrhoeae* isolates.
367 24:30–34. <https://doi.org/10.1089/mdr.2017.0054>.
- 368 18. Hermesen ED, Hovde LB, Konstantinides GN, Rotschafer JC. 2005. Mutant
369 prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and
370 gatifloxacin against three common respiratory pathogens. *Antimicrob Agents*
371 *Chemother* 49:1633–1635. <https://doi.org/10.1128/AAC.49.4.1633-1635.2005>.
- 372 19. Azargun R, Soroush B MH, Samadi KH, Ahangar OM, Sadeghi V, Memar MY,
373 Ghotaslou R. 2018. The frequency of DNA gyrase and topoisomerase IV
374 mutations, and plasmid-mediated quinolone resistance genes among *Escherichia*
375 *coli* and *Klebsiella pneumoniae* isolated from urinary tract infections in
376 Azerbaijan, Iran. *J Glob Antimicrob Resist* 13.pil:S2213-7165(18)30219-4.
377 <https://doi.org/10.1016/j.jgar.2018.11.003>.
- 378 20. Kim MC, Woo GJ. 2017. Characterization of antimicrobial resistance and
379 quinolone resistance factors in high-level ciprofloxacin-resistant *Enterococcus*
380 *faecalis* and *Enterococcus faecium* isolates obtained from fresh produce and
381 fecal samples of patients. *J Sci Food Agric* 97:2858–2864.
382 <https://doi.org/10.1002/jsfa.8115>.

- 383 21. Cherkaoui A, Gaia N, Baud D, Leo S, Fischer A, Ruppe E, Francois P, Schrenzel
384 J. 2018. Molecular characterization of fluoroquinolones, macrolides, and
385 imipenem resistance in *Haemophilus influenzae*: analysis of the mutations in
386 QRDRs and assessment of the extent of the AcrAB-TolC-mediated resistance.
387 Eur J Clin Microbiol Infect Dis 37:2201–2210.
388 <https://doi.org/10.1007/s10096-018-3362-2>.
- 389 22. Cantisani M, Vitiello M, Falanga A, Finamore E, Galdiero M, Galdiero S. 2012.
390 Peptides complementary to the active loop of porin P2 from *Haemophilus*
391 *influenzae* modulate its activity. Int J Nanomedicine 7:2361–2371.
392 <https://doi.org/10.2147/IJN.S30467>.
- 393 23. Kattner C, Pfenning S, Massari P, Tanabe M. 2015. One-step purification and
394 porin transport activity of the major outer membrane proteins P2 from
395 *Haemophilus influenzae*, FomA from *Fusobacterium nucleatum* and PorB from
396 *Neisseria meningitidis*. Appl Biochem Biotechnol 175:2907–2915.
397 <https://doi.org/10.1007/s12010-014-1473-2>.
- 398 24. Li XZ, Plesiat P, Nikaido H. 2015. The challenge of efflux-mediated antibiotic
399 resistance in Gram-negative bacteria. Clin Microbiol Rev 28:337–418.
400 <https://doi.org/10.1128/CMR.00117-14>.

- 401 25. Adamus-Bialek W, Baraniak A, Wawszczak M, Gluszek S, Gad B, Wrobel K,
402 Bator P, Majchrzak M, Parniewski P. 2018. The genetic background of antibiotic
403 resistance among clinical uropathogenic *Escherichia coli* strains. Mol Biol Rep
404 45:1055–1065. <https://doi.org/10.1007/s11033-018-4254-0>.
- 405 26. Davies TA, Kelly LM, Hoellman DB, Ednie LM, Clark CL, Bajaksouzian S,
406 Jacobs MR, Appelbaum PC. 2000. Activities and postantibiotic effects of
407 gemifloxacin compared to those of 11 other agents against *Haemophilus*
408 *influenzae* and *Moraxella catarrhalis*. Antimicrob Agents Chemother 44:633–
409 639.
410

Figure Legends

412

413 Figure 1. Percentages of BLNAR and β -lactamase-positive *Haemophilus influenzae*
 414 isolates in different years: Percentages of BLNAR isolates increased to be 15.0% in
 415 2015, 43.5% in 2016, and 63.6% in 2017. β -Lactamase-producing isolates accounted for
 416 15.2% in 2017.

417 Figure 2a-f. MIC values of fluoroquinolones for *Haemophilus influenzae* isolates in
 418 different years

419 a: MXF MICs in different years; Isolates showing MIC value of ≥ 0.5 were detected,
 420 those with MIC value of ≤ 0.03 accounted for $\leq 80\%$, and the susceptibility decreased
 421 every year since 2013, except for 2015.

422 b: CIP MICs in different years: The susceptibility is mostly maintained, although
 423 isolates with MIC value of ≥ 0.5 were detected since 2014.

424 c: LVX MICs in different years: The susceptibility is mostly maintained, although
 425 isolates with MIC value of ≥ 0.5 were detected since 2014.

426 d: GRNX MICs in different years: The susceptibility is mostly maintained, although
 427 isolates with MIC value of 0.5 were detected in 2013, 2014, and 2017.

428 e: TFLX MICs in different years: The susceptibility is mostly maintained, although
429 isolates with MIC value of 1 were detected in 2017.

430 f: STFX MICs in different years; The susceptibility is nearly absolutely maintained, as
431 all isolates had MIC value of ≤ 0.06 .

432 Figure 3 a-b. Correlation between MIC value of MXF and MIC values of other
433 fluoroquinolones against *Haemophilus influenzae* (comparison in the same isolates)

434 a: Correlation between MIC values of CIP and MXF: In a range of $0.25 \leq \text{MIC} \leq 1.0$,
435 MIC value of MXF was higher than that of CIP in 64.7% of isolates.

436 b: Correlation between MIC values of LVX and MXF: In a range of $0.25 \leq \text{MIC} \leq 1.0$,
437 MIC value of MXF was higher than that of LVX in 70.6% of isolates.

438

439 Table 1. Association between low quinolone susceptibility and QRDR mutations

440

TABLE 1 Association between low quinolone susceptibility and QRDR mutations

Strain							Mutation	
	MFLX	CPFX	GRNX	LVFX	TFLX	STFX	GyrA	ParC
2012—1	1	0.25	1	0.25	0.25	0.06	Ser84Leu	—
2012—2	0.25	0.03	0.12	0.06	0.03	0.03	—	Gly82Arg
2013—1	0.5	0.25	0.5	0.25	0.25	0.03	Ser84Leu	—
2014—1	0.5	0.25	0.5	0.25	0.25	0.03	Ser84Leu	—
2014—2	0.5	0.25	0.5	0.12	0.12	0.03	Ser84Leu	—
2014—3	0.5	0.25	0.25	0.25	0.12	0.03	Ser84Leu	—
2014—4	0.25	0.12	0.25	0.12	0.06	0.03	Ser84Leu	—
2014—5	0.5	0.5	0.12	0.5	0.12	0.03	—	—
2014—6	0.25	0.03	0.06	0.06	0.06	0.03	—	—
2014—7	0.25	0.03	0.06	0.03	0.06	0.03	—	—
2015—1	0.25	0.5	0.06	0.5	0.12	0.03	—	—
2016—1	0.5	0.5	0.25	1	0.12	0.03	Ser84Leu	—
2016—2	0.5	0.5	0.12	0.5	0.12	0.03	Ser84Leu	—
2016—3	0.25	0.03	0.06	0.03	0.03	0.03	—	—
2017—1	1	1	0.5	0.5	1	0.06	—	Ser84Ile
2017—2	0.5	1	0.25	0.5	1	0.03	Ser84Leu	Ser84Ile
2017—3	0.5	0.03	0.12	0.03	0.03	0.03	—	—

a

CIP						n = 144
1					1	1
0.5				1	3	
0.25					4	1
0.12			1		1	
0.06			1			
0.03	71	43	11	4	1	
	0.03	0.06	0.12	0.25	0.5	1

b

LVX						
						n = 144
1					1	
0.5				1	3	1
0.25					3	1
0.12					2	
0.06			2	2		
0.03	71	43	11	2	1	
	0.03	0.06	0.12	0.25	0.5	1

MXF